The goal of this pilot clinical trial is to assess the effectiveness of psychodramatic psychotherapy in reducing the psychological distress and/or the skin condition in patients with vitiligo.
The main questions it aims to answer are:
1. Is there any improvement in terms of psychological distress in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group?
2. Is there any improvement in terms of skin condition in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group? Participants in the experimental group will receive the dermatological drug treatment usually recommended for vitiligo, and in addition they will participate in a 6 months psychodramatic psychotherapy.
Researchers will compare the results of the experimental group with the results of a control group including vitiligo patients who will receive the dermatological pharmacological treatment usually recommended for vitiligo and participate in a 6 months program of self-help activities.

Start Date02 Nov 2023

Sponsor / Collaborator

Università degli Studi di Brescia

[+1]

NCT05988333

/ RecruitingNot ApplicableIIT

The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial

Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.

Start Date27 Sep 2023

Sponsor / Collaborator

University of Campania Luigi Vanvitelli

[+18]

NCT05726513

/ RecruitingNot ApplicableIIT

Evaluation of Regional Ventilation Distribution Using Electrical Impedance Tomography During Weaning From Mechanical Ventilation

The goal of this physiological cross-over clinical trial is to evaluate the effect of different clinically used weaning trials on regional mechanical ventilation in a population of patients undergoing weaning from mechanical ventilation for acute respiratory failure.
The main question[s] it aims to answer are:
to evaluate which weaning trial is associated to a better regional ventilation distribution
to evaluate which weaning trial can be comparable to ventilation distribution after extubation
Participants will undergo 3 clinically used weaning trials in a random order (cross-over trial). Researchers will compare the different steps to see if regional ventilation distribution is different among the different trial .

Start Date15 Feb 2023

Sponsor / Collaborator

Università degli Studi di Brescia

[+1]

100 Clinical Results associated with Università degli Studi di Brescia

0 Patents (Medical) associated with Università degli Studi di Brescia

25,508

Literatures (Medical) associated with Università degli Studi di Brescia

31 Dec 2025·Italian Journal of Animal Science

Effects of dietary supplementation with olive cake enriched in polyphenols on growth, rumen fermentation, and metabolic status of finishing Limousine bulls

Author: Ferronato, G. ; Amato, A. ; Cavallo, C. ; Trevisi, E. ; Chiofalo, V. ; Llobat, L. ; Liotta, L. ; Lopreiato, V.

The integration of olive cake in ruminants diet can represent a path to reduce environmental impact and cost-associated disposal.Finishing Limousine bulls supplemented with olive cake showed higher rumen propionate and heptanoate and lower acetate, isobutyrate, and isovaleriate content than control bulls.The supplementation of olive cake influenced metabolic, liver, and antioxidant markers in finishing Limousine bulls, suggesting it could have not well understood effects on their health status.

31 Dec 2025·Annals of Medicine

Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia

Article

Author: El Masri, Yehia ; Levi, Guido ; Muiesan, Maria Lorenza ; Cattaneo, Sergio ; Guerini, Michele ; Capuccini, Silvia ; Violini, Manuela ; Tomasoni, Gabriele ; Giannini, Alberto ; Peli, Elena ; Piras, Stefano ; Tantucci, Claudio ; Giordani, Jordan ; Zubani, Francesca ; Palazzi, Irene ; Piva, Simone ; Borghesi, Andrea ; Assanelli, Deodato ; Barbieri, Silvia ; Visca, Dina ; Pini, Alessandro ; Pini, Laura ; Maroldi, Roberto ; Latronico, Nicola ; Guarneri, Bruno

BACKGROUNDPersistent respiratory symptoms and impaired gas exchange are common in patients recovering from COVID-19 pneumonia. The Lung Diffusing Capacity for Carbon Monoxide (DLCO) and Carbon Monoxide Transfer Coefficient (KCO) do not adequately distinguish alveolar membrane dysfunction from vascular abnormalities. This study aimed to characterize persistent diffusion impairment in post-ICU patients with prior SARS-CoV-2 pneumonia and reduced DLCO.METHODSAfter hospital discharge, patients underwent spirometry, DLCO measurement, and a 6-minute walking test every six months. If DLCO remained impaired at 18-24 months, a combined Lung Diffusing Capacity for Nitric Oxide (DLNO) and DLCO assessment was performed to differentiate alveolar-capillary membrane (DmCO) and pulmonary capillary blood volume (Vc) alterations.RESULTSAmong 20 patients with persistent DLCO reduction, 3 had an obstructive ventilatory pattern, 6 had restriction, and 12 had low KCO. In restrictive cases, KCO was reduced but remained within normal limits without compensation. The DLNO/DLCO ratio exceeded 113.5% predicted in all patients. DmCO was impaired in 7 patients, while Vc was reduced in 16.CONCLUSIONBoth DLCO determinants were affected, with vascular impairment predominating. Vc reduction was present in most patients, with mean values below the lower limit of normality, whereas DmCO was less affected and often normal. The elevated DLNO/DLCO ratio suggests that persistent DLCO reduction is primarily driven by prolonged pulmonary capillary circulation dysfunction rather than alveolar membrane alterations, highlighting the vascular component as the primary site of long-term impairment.

01 Jul 2025·Gait & Posture

Gait improvements in the early post-surgery rehabilitation phase in subjects receiving a total knee or hip arthroplasty: A prospective study

Article

Author: Pollet, Joel ; Buraschi, Riccardo ; Falso, Maurizio V ; Pullara, Rosa ; Bianchi, Luca N C ; Gobbo, Massimiliano

BACKGROUNDRehabilitation after total knee arthroplasty (TKA) and total hip arthroplasty (THA) is fundamental for reducing pain and recovering strength, range of motion, and walking ability. Gait analysis (GA) is rarely included in the rehabilitation path. This study assesses how inpatient rehabilitation influences clinical outcomes and gait analysis (GA) parameters in TKA and THA patients, comparing these with age- and speed-matched healthy subjects (HS).METHODSA prospective observational study included 80 subjects (50 TKA, 30 THA) and 20 aged-matched HS. Assessments occurred at admission and discharge post inpatient rehabilitation, using clinical outcome scales (e.g., Modified Barthel Index, Knee Society Score), GA spatiotemporal parameters, and gait summary measures (e.g., Gait Profile Score, Gait Deviation Index). Statistical analyses determined the significance of improvements.RESULTSPost-rehabilitation, significant improvements were observed in clinical outcomes and some key spatio-temporal gait parameters (p ≤ 0.01). However, gait summary measures showed no changes. Interestingly, gait summary measures did not correlate with clinical outcome scales. Moreover, TKA and THA patients showed no differences compared with slow-walking HS.CONCLUSIONInpatient rehabilitation significantly enhanced clinical outcomes and spatio-temporal parameters. Additionally, no differences were observed between spatiotemporal and gait summary measures of slow-walking HS and patients at discharge, indicating that rehabilitation restored gait quality. However, gait speed remains impaired, in both TKA and THA populations. Future research should explore personalized rehabilitation protocols to address these limitations and improve gait outcomes.TRIAL REGISTRATION NUMBERNCT04803578.

News (Medical) associated with Università degli Studi di Brescia

19 Jan 2022

·www.nsmedicaldevices.com

Diadem gets FDA breakthrough status for blood test to detect Alzheimer’s

AlzoSure is the first prognostic blood test to predict the likeliness of Alzheimer's disease progression, up to six years in advance Diadem’s AlzoSure is a blood test that predicts Alzheimer’s disease. Diadem has received the US Food and Drug Administration (FDA) Breakthrough Device Designation for the AlzoSure Predict blood test to predict the Alzheimer’s disease (AD). According to the company, AlzoSure Predict is a blood-based biomarker prognostic assay intended for the early prediction of AD. The test identifies the chances of Alzheimer’s disease progression in cognitive impairment patients, aged 50 years and above, up to six years prior to the onset of definitive symptoms. Diadem CEO Paul Kinnon said: “Obtaining this FDA Breakthrough Device designation reinforces our view that AlzoSure Predict is a potential game changer for the early identification and management of Alzheimer’s disease, which afflicts millions of patients and their families worldwide. “We see the Breakthrough Device designation as an important step in supporting the future commercialization of AlzoSure Predict in the US and globally, and we look forward to working closely with the FDA to complete our clinical studies and expedite the regulatory review process.” Diadem’s regulatory application with the US FDA was based on positive data from a study of AlzoSure Predict in 482 cognitive impairment patients, aged 50 years or older. The study showed that AlzoSure Predict is capable of identifying the likeliness of disease progression to full-fledged AD, up to six years prior to the symptomatic illness. The second phase of this study, which includes biobank data on more than 1,000 additional patients from the US and Europe, is anticipated to be completed in the coming months. Alzheimer’s disease is the most common form of dementia that accounts for 60-70% of cases, with no disease modifying treatments, and limited therapies to treat symptoms. Diadem, a spin-off from the University of Brescia, Italy, is developing AlzoSure Predict as a simple, non-invasive plasma-based biomarker assay to predict the progression of AD. The company’s leverages its patented antibody technology to target U-p53AZ, a conformational variant of the p53 protein, and its sequences.

Antibody

100 Deals associated with Università degli Studi di Brescia

100 Translational Medicine associated with Università degli Studi di Brescia

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

UniPR-1331 ( EphA2 )	Solid tumor More	Preclinical
Diprenorphine ( μ opioid receptor )	Opiate Overdose More	Preclinical
CB2 modulators(Università degli Studi di Brescia) ( CB2 )	Inflammation More	Discovery
Hepcidin Inhibition(University of Brescia) ( Hepc )	Anemia More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis